NIH Funding Secured for Phase 2 Clinical Trial of Novel Antibiotic Candidate, CRS3123

Sep 12, 2019 | Press Releases

Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate, CRS3123 to Treat C. difficile infection. 

Learn More:

https://www.businesswire.com/news/home/20190912005834/en/Crestone-Boulder-Secures-NIH-Funding-Phase-2